Clinical Trial: Trial of Minocycline to Treat Children With Fragile X Syndrome

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome

Brief Summary: This is a single center study at the UC Davis MIND Institute in patients age 3.5-16 years of age with fragile X syndrome (FXS), funded by a National Fragile X Foundation Grant. It is a controlled trial of minocycline, an antibiotic commonly used in children for infection or for treatment of neurodegenerative disorders. We are investigating its use in FXS because it lowers matrix metalloproteinase 9 (MMP9) levels, which are high in FXS, and it also strengthens brain connections in the animal models of FXS. We hypothesize that minocycline will likely be helpful for language, behavior and/or cognition in fragile X patients.